- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02156856
Stroke Volume Analysis During Aortic Valve Replacement Trial (standart)
7. august 2014 oppdatert av: Michael Sander, Charite University, Berlin, Germany
Compromised peripheral tissue oxygenation during surgery may lead to worse patient outcome, mainly due to post-operative infections or heart failure.
Insufficient stroke volume and/or cardiac output due to hypovolemia or cardiac defects play a central role in causing poor peripheral tissue oxygenation.
In order to assess stroke volume, there are numerous invasive and non-invasive methods available.
Up to the present date it is unknown, if these methods may by used interchangeably in patients with severe cardiac defects like aortic stenosis.
Studieoversikt
Status
Ukjent
Studietype
Observasjonsmessig
Registrering (Forventet)
68
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Charité Universitätsmedizin Berin
-
Underetterforsker:
- Felix Balzer, MD
-
Ta kontakt med:
- Michael Sander, MD
- Telefonnummer: +4930450531052
- E-post: michael.sander@charite.de
-
Underetterforsker:
- Sascha Treskatsch, MD
-
Underetterforsker:
- Marit Habicher, MD
-
Underetterforsker:
- Viktor Mezger, MD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Cardiac surgery at a university hospital
Beskrivelse
Inclusion Criteria:
- scheduled transcatheter aortic valve implantation
- signed patient consent form
- aged 18 or older by time of surgery
- no participation in other clinical trials
Exclusion Criteria:
- pregnant or breast-feeding women
- emergency surgery
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Hemodynamic optimisation
|
|
No hemodynamic optimisation
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Measurement of stroke volume (ml) before TAVI (transcatheter aortic valve implantation) by means of (1) FloTrac, (2) transesophageal doppler echocardiography, (3) pulmonary thermodilution via pulmonary artery catheter
Tidsramme: Before Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Measurement of cardiac output (l/min) before TAVI (transcatheter aortic valve implantation) by means of (1) FloTrac, (2) transesophageal doppler echocardiography, (3) pulmonary thermodilution via pulmonary artery catheter
Tidsramme: Before Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Measurement of stroke volume (ml) after TAVI (transcatheter aortic valve implantation) by means of (1) FloTrac, (2) transesophageal doppler echocardiography and (3) pulmonary thermodilution via pulmonary artery catheter
Tidsramme: After surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
After surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Accordance of stroke volume and cardiac output measurements assessed by (1) FloTrac, (2) transesophageal doppler echocardiography and (3) pulmonary thermodilution via pulmonary artery catheter AFTER ADMINISTRATION OF FLUID BOLUS
Tidsramme: Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Accordance of stroke volume and cardiac output measurements assessed by two of the mentioned methods [i.e. (1) FloTrac, (2) transesophageal doppler echocardiography and (3) pulmonary thermodilution via pulmonary artery catheter]
Tidsramme: Before and after Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before and after Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Measurement of cardiac output (l/min) after TAVI (transcatheter aortic valve implantation) by means of (1) FloTrac, (2) transesophageal doppler echocardiography and (3) pulmonary thermodilution via pulmonary artery catheter
Tidsramme: After Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
After Surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
oxygen delivery (ml)
Tidsramme: Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
image quality of echocardiography
Tidsramme: Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Before and after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Length of stay on ICU
Tidsramme: participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Cumulative rate of infections
Tidsramme: after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
incidence of delirium after surgery
Tidsramme: after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
dosage of inotropic medication (mg/d)
Tidsramme: after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
length of hospital stay
Tidsramme: after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
incidence of stroke
Tidsramme: after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
after surgery; participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Michael Sander, MD, Charite University, Berlin, Germany
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2014
Primær fullføring (Forventet)
1. mai 2015
Datoer for studieregistrering
Først innsendt
20. mai 2014
Først innsendt som oppfylte QC-kriteriene
2. juni 2014
Først lagt ut (Anslag)
5. juni 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
8. august 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. august 2014
Sist bekreftet
1. august 2014
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- EA1/060/13
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .